Effect of L-364,718 on pancreatic endocrine function following partial pancreatectomy.
This study was designed to determine the effect of a potent cholecystokinin antagonist, L-364,718, on canine pancreatic endocrine function following partial pancreatectomy. Plasma glucose, insulin, and glucagon were determined over a 2-hr interval following an intravenous bolus of 0.5 g/kg glucose in a 50% solution. The following groups were established: normal animals (group A, n = 5), normal animals pretreated with 20 nmole/kg L-364,178 (group B, n = 5), partially pancreatectomized animals (group C, n = 5), and partially pancreatectomized animals pretreated with 20 nmole/kg L-364,178 (group D, n = 5). In contrast to animals with an intact pancreas, pretreatment with L-364,718 following partial pancreatectomy resulted in a significant decrease in peak insulin (group C = 132.8 +/- 13.0 microU/ml vs Group D = 90.4 +/- 16.1 microU/ml, P < 0.05) and the basal-to-peak insulin difference (group C = 111.9 +/- 11.5 microU/ml vs group D = 77.5 +/- 16.6 microU/ml, P < 0.05). Despite this, the rate of glucose utilization (K value) was significantly increased in the partially pancreatectomized animals given the antagonist (group C = -1.22 +/- 0.22%/min vs group D = -2.79 +/- 0.427%/min) and there were no significant differences in basal or peak glucose when comparing the groups given L-364,718 with the groups given placebo (group A vs B and group C vs D). Thus, the CCK antagonist L-364,718 significantly decreases peak insulin in partially pancreatectomized animals but not in nonoperative control animals. There is a paradoxical increase in the rate of glucose utilization but no effect on glucose homeostasis. The effect of this antagonist in other models of reduced islet cell reserve (i.e., pancreas transplantation) remains to be determined.
Presti
M E
ME
Department of Surgery, St. Louis University Health Sciences Center, St. Louis, Missouri 63110-0250, USA.
Niehoff
M L
ML
Burton
F R
FR
Solomon
H
H
Garvin
P J
PJ
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology*; D001786:Blood Glucose / Q000187:drug effects; D002452:Cell Count; D020109:Devazepide; D004285:Dogs; D005260:Female; D005934:Glucagon / Q000097:blood; D005947:Glucose / Q000378:metabolism; D006727:Hormone Antagonists / Q000494:pharmacology*; D007328:Insulin / Q000097:blood; D007515:Islets of Langerhans / Q000166:cytology; D010179:Pancreas / Q000166:cytology / Q000187:drug effects* / Q000601:surgery; D010180:Pancreatectomy; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors
D001570:Benzodiazepinones; D001786:Blood Glucose; D006727:Hormone Antagonists; D007328:Insulin; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; D005934:Glucagon; D005947:Glucose; D020109:Devazepide